SHIELD THERAPEUTICS PLC
Shield Therapeutics plc (company number 09761509) is a public limited company registered in England and Wales, incorporated on 3 September 2015, with its registered office at Northern Design Centre, Baltic Business Quarter, Gateshead Quays, NE8 3DF. Its registry status at Companies House is recorded as active, and it is registered under UK Standard Industrial Classification code 86900, “other human health activities.”
Shield Therapeutics plc is a commercial-stage specialty pharmaceutical company focused on the treatment of iron deficiency, with or without anaemia. Its lead product is ferric maltol, an oral iron replacement therapy marketed as Accrufer in the United States and Feraccru in the European Union, United Kingdom and Switzerland, where it is approved for use in adults. In 2026 the US Food and Drug Administration accepted, with priority review, a submission to extend the Accrufer label to adolescent patients with iron deficiency anaemia, with a regulatory decision expected later in the year.
Shield Therapeutics plc’s ordinary shares have been admitted to trading on AIM, a market operated by the London Stock Exchange, under the ticker STX; the shares also trade in the United States on the OTCQB market under the symbol SHIEF.
For the financial year ended 31 December 2025, the Shield Therapeutics Group reported net revenues and other income of US$49.7 million, with US net revenue from Accrufer growing 56 percent year-on-year to US$45.8 million and ex-US revenue of US$3.9 million generated mainly from royalty and milestone payments on European product sales, as announced on 9 April 2026. These are consolidated group figures rather than standalone company-level results. Approximately 199,000 Accrufer prescriptions were dispensed in the United States during 2025 at an average net selling price of US$223, and the group’s reported loss for the year narrowed to US$17.7 million from US$27.2 million in 2024, with positive net operating cash flow recorded in the fourth quarter of 2025.
- Company fundamentals
- Corporate linkage & group structures
- Digitized company financials
- Firmographics — websites, social profiles, revenue and employee estimates
Shareholders
Based on the People with Significant Control (PSC) register maintained by Companies House, Shield Therapeutics plc has one active person with significant control on record. AOP Health International Management AG, a corporate entity registered in Ruggell, Liechtenstein, was notified on 1 August 2022 as holding, directly or indirectly, ownership of shares and voting rights of more than 25 percent but not more than 50 percent. A previous significant controller, Nestle S.A. (Switzerland), was notified on 26 June 2017 in the same ownership band and ceased to be a registered PSC on 1 September 2022. Because Shield Therapeutics plc is a public company admitted to trading on AIM, the PSC register captures only holders crossing statutory control thresholds rather than the complete shareholder base. Following a convertible-loan conversion completed in May 2023, AOP Health International Management AG and parties acting in concert were reported, via London Stock Exchange regulatory news, to hold approximately 41.9 percent of voting rights, which triggered a mandatory cash offer for the company under Rule 9 of the UK Takeover Code; that offer lapsed in June 2023 without the bidder gaining control. Market-data aggregators have since reported AOP Health International Management AG’s holding at just above 50 percent, but this figure could not be independently confirmed against an official TR-1 disclosure or an updated Companies House filing during this review, and is presented here as unverified.
Data availability
Classification: Major shareholders only. The Companies House PSC register identifies statutory significant controllers crossing the 25 percent threshold but does not provide a complete list of shareholders or exact current percentages, and the most recent PSC notification (August 2022) predates the May 2023 loan conversion and mandatory offer, so the register may understate AOP Health International Management AG’s current holding.
Sources
- Companies House, People with Significant Control register for Shield Therapeutics plc (find-and-update.company-information.service.gov.uk), retrieved 11 September 2026
- London Stock Exchange RNS, “AOP Loan Conversion and Mandatory Cash Offer,” Shield Therapeutics plc, May 2023
- Slaughter and May, deal summary on AOP Health International Management AG’s mandatory cash takeover offer for Shield Therapeutics plc
Officers
14
As of September 2026, Companies House records seven active officers for Shield Therapeutics plc, comprising six directors and one company secretary, within a total of 14 officer records including historical appointments. The current directors are Hans Peter Hasler (appointed 26 July 2018), Peter Llewellyn-Davies (appointed 26 February 2016), Dr Christian Karl Kurt Schweiger (appointed 26 June 2020), Maria Fabiana Lacerca-Allen (appointed 10 May 2021), Karl Anders Lundstrom (appointed 10 May 2021) and Dr Rudolf Stefan Widmann (appointed 3 July 2024). Lucy Kate Huntington-Bailey has served as company secretary since 1 September 2017. Where officially disclosed at Companies House, nationality is recorded as Swiss for Hasler (resident in Switzerland), British for Llewellyn-Davies (resident in Germany), German and Swiss for Schweiger (resident in Switzerland), Argentine and American for Lacerca-Allen (resident in the United States), Swedish and American for Lundstrom (resident in the United States), and Austrian for Widmann (resident in Austria); nationality is not listed for the company secretary. All director correspondence addresses on file are the company’s registered office in Gateshead, which is a service address and is not used here to infer residence or nationality.
Recent officer changes
- Dr Rudolf Stefan Widmann appointed Director, effective 3 July 2024 (source: Companies House).
- Gregory Paul Madison, a director since 18 June 2021, resigned effective 24 July 2024 (source: Companies House).
Data availability
Classification: Full. Companies House publishes current and historical officer appointments, resignation dates and, for directors, officially disclosed nationality and country of residence. The profile’s previously held internal officer data significantly understated the current board, listing only historical resigned directors rather than the officers presently on file at Companies House.
Sources
- Companies House, Officers register for Shield Therapeutics plc (find-and-update.company-information.service.gov.uk), retrieved 11 September 2026
Registry feed — rows exactly as filed with Companies House, including entries the profile above does not cover.
Group Structure
Shield Therapeutics plc is not wholly independent. The Companies House PSC register identifies AOP Health International Management AG, a corporate entity registered in Ruggell, Liechtenstein, as an active person with significant control, notified 1 August 2022 with ownership of shares and voting rights of more than 25 percent but not more than 50 percent, making it the company’s immediate and, on currently verified information, ultimate identified parent-level controller. AOP Health International Management AG forms part of the wider AOP Health Group, a pharmaceutical group headquartered in Vienna, Austria; no further verified ultimate parent above AOP Health International Management AG was identified through an authoritative UK source. Shield Therapeutics plc is itself the parent of one identified subsidiary, Phosphate Therapeutics Ltd. (company number 07618820), a private limited company registered in England and Wales in which Shield Therapeutics plc has been recorded as holding 75 percent or more of shares since 6 April 2016; Companies House records Phosphate Therapeutics Ltd.’s current status as being in liquidation. No other verified subsidiaries were identified.
Verified corporate relationships
| Entity | Country | Registration number | Relationship | Ownership | Status | Information date |
|---|---|---|---|---|---|---|
| AOP Health International Management AG | Liechtenstein | Not disclosed in UK filing | Significant controller (parent-level) | More than 25% up to 50% of shares and voting rights | Active | 1 August 2022 |
| Phosphate Therapeutics Ltd. | United Kingdom | 07618820 | Direct subsidiary | 75% or more of shares | Liquidation | 6 April 2016 |
Recent structural changes
- May 2023: AOP Health International Management AG converted a convertible loan into Shield Therapeutics plc shares, increasing its stake, together with concert parties, to approximately 41.9 percent of voting rights and triggering a mandatory cash offer under Rule 9 of the UK Takeover Code; the offer lapsed in June 2023 without the bidder gaining control (source: London Stock Exchange RNS).
- 1 September 2022: Nestle S.A. ceased to be a registered person with significant control of Shield Therapeutics plc (source: Companies House).
Data availability
Classification: Partial. UK registries confirm one active and one historical corporate significant controller of Shield Therapeutics plc, and confirm one direct UK subsidiary, but do not disclose a registration number for the Liechtenstein-registered parent-level entity or any ownership stake held elsewhere within the wider AOP Health Group, and do not confirm whether Shield Therapeutics plc holds interests in any non-UK subsidiaries. Market-data aggregators, which are not independently verified official filings, suggest AOP Health International Management AG’s holding has increased since its August 2022 PSC notification.
Sources
- Companies House, PSC register for Shield Therapeutics plc, retrieved 11 September 2026
- Companies House, company and PSC records for Phosphate Therapeutics Ltd. (company number 07618820), retrieved 11 September 2026
- London Stock Exchange RNS, “AOP Loan Conversion and Mandatory Cash Offer,” Shield Therapeutics plc, May 2023
- AOP Health, “AOP Health Group” company overview (aop-health.com)
SHIELD THERAPEUTICS PLC
United Kingdom
Get complete shareholder and officer records, ultimate beneficial owner resolution, and ongoing ownership monitoring.
Frequently Asked Questions
What does SHIELD THERAPEUTICS PLC do?
Shield Therapeutics plc (company number 09761509) is a UK public limited company incorporated on 3 September 2015 and recorded as active at Companies House. It is a commercial-stage specialty pharmaceutical company focused on iron deficiency treatment, marketing ferric maltol as Accrufer in the United States and Feraccru in the EU, UK and Switzerland.
Who owns SHIELD THERAPEUTICS PLC?
Companies House records AOP Health International Management AG (Liechtenstein) as the sole active person with significant control, holding more than 25 percent but not more than 50 percent of shares and voting rights, notified 1 August 2022; a 2023 loan conversion reportedly raised this stake to about 41.9 percent, triggering a mandatory takeover offer that later lapsed.
Who is SHIELD THERAPEUTICS PLC's UBO (Ultimate Beneficial Owner)?
No natural-person ultimate beneficial owner is disclosed for Shield Therapeutics plc; its significant controller, AOP Health International Management AG, is itself a corporate entity, and no further verified ownership chain was identified through an authoritative UK source.
What is SHIELD THERAPEUTICS PLC's company registration number?
SHIELD THERAPEUTICS PLC's registration number is 09761509, filed with Companies House in United Kingdom. Its current status on the register is active.
Is SHIELD THERAPEUTICS PLC still an active company?
SHIELD THERAPEUTICS PLC's status on Companies House is listed as active.
When was SHIELD THERAPEUTICS PLC incorporated?
SHIELD THERAPEUTICS PLC was incorporated on 3 September 2015, according to Companies House.
What is SHIELD THERAPEUTICS PLC's registered address?
The registered address on file for SHIELD THERAPEUTICS PLC is Gateshead Quays, United Kingdom.
What legal structure is SHIELD THERAPEUTICS PLC registered as?
SHIELD THERAPEUTICS PLC is registered as a Public Limited Company in United Kingdom.
What is SHIELD THERAPEUTICS PLC's revenue?
For the year ended 31 December 2025, the Shield Therapeutics Group reported consolidated net revenues and other income of US$49.7 million, with US Accrufer net revenue up 56 percent to US$45.8 million, as announced 9 April 2026.
Is SHIELD THERAPEUTICS PLC listed on a stock exchange?
Shield Therapeutics plc ordinary shares trade on AIM, a market of the London Stock Exchange, under ticker STX, and on the US OTCQB market under symbol SHIEF.
Who are the officers/directors of SHIELD THERAPEUTICS PLC?
Companies House lists seven active officers for Shield Therapeutics plc as of September 2026: six directors, including Hans Peter Hasler, Peter Llewellyn-Davies and Dr Christian Schweiger, plus company secretary Lucy Kate Huntington-Bailey; Dr Rudolf Widmann was appointed director on 3 July 2024.
Does SHIELD THERAPEUTICS PLC have a parent company or subsidiaries?
Shield Therapeutics plc immediate significant controller is AOP Health International Management AG (Liechtenstein), part of the Vienna-headquartered AOP Health Group; Shield Therapeutics plc itself holds 75 percent or more of Phosphate Therapeutics Ltd. (company number 07618820), a UK subsidiary now recorded as in liquidation.
Can Zavia monitor changes to SHIELD THERAPEUTICS PLC's ownership over time?
This profile reflects a point-in-time snapshot from Companies House. Zavia's monitoring API can track changes to SHIELD THERAPEUTICS PLC's registered shareholders, officers, and group structure going forward, flagging updates as they're filed rather than requiring a manual recheck.
Can I access SHIELD THERAPEUTICS PLC's data through an API?
Yes. Zavia's API connects directly to official government ownership registries across 195 countries and territories, including United Kingdom, so records like SHIELD THERAPEUTICS PLC's registration, shareholder, UBO, and group-structure data can be queried programmatically instead of viewed one page at a time.
Where does this company information come from, and how current is it?
This record is sourced directly from Companies House and was last synced on 8 September 2026.